GSK, Howson, Hengrui, Xinlitai and other pharmaceutical companies have not selected varieties to actively reduce prices

According to the notice, GlaxoSmithKline (Tianjin) Co., Ltdand other enterprises to take the initiative to apply for a reduction in the alliance region (Zhejiang) drug centralized procurement of non-selected products in Zhejiang online transaction prices, price adjustment from December 25 to implementprice adjustment list is as follows:the non-selected varieties actively reduce pricein the first round of 4 plus 7, for the unselected varieties, the strength of the gradient price reduction is not small, for example, Novartis's original drug, methasultinic imatinib (100mg x 60 tablets), in Shanghai price fell to 7182 yuan, after its winning bid in all provinces of the country was about 10,000 yuan;such as Shi Guibao's Entikave tablets (0.5mg x 7 pieces), after the price of Liaoning price of 141.53 yuan, after its winning bid in the provinces about 200 yuan;Although the specific price reduction of the above-mentioned varieties is not officially disclosed, but review the price reduction of the first round of 4 plus 7 unselected varieties, we can also guess that the price reduction of the unselected varieties should not be smallat present, in the 4 plus 7 expansion of the results of the landing implementation, all over the place is also deploying the non-selected drugs gradient price reduction workSeiber Blue inquiry around the announcement found that, so far, Hainan, Liaoning, Shanghai, Sichuan, Chongqing, Tianjin, Shanxi, Shaanxi and many other regions, has issued a request for "4 plus 7" the same varieties of unselected drugs gradient price reductionFor example, Hainan Province on December 16 issued "on the public drug centralized procurement expansion of the price reduction of unselected varieties." After combing, Hainan a total of 149 product rules choose to reduce prices, in the need for gradient price reduction in the number of more than half of the rulesAccording to the notification requirements, the non-reduced prices of varieties will be removed from the networkLiaoning also issued on October 22 "on the implementation of the Alliance Region (Liaoning Province) drug centralized procurement varieties of unselected drug gradient price reduction notice", requiring unselected enterprises gradient price reduction, can not complete the declaration on time, will be disqualified from the network, a total of 310 drugs involveda large number of drugs, the arrival of the price reduction tide
whether you have noticed that the above-mentioned price adjustment notice in Zhejiang Province, there is a "linkage" wordIt is not difficult to understand, with the current national price linkage, once in a province and city to determine the price reduction, under the price linkage, the price of national unity will be a big probability eventin addition, in the first round of 4 plus 7 landing implementation, the National Health Insurance Administration has officially announced the 4 plus 7 unselected products medical insurance payment standards, the document clearly: will be 4 plus 7 set of selected prices as the medical insurance payment standards, beyond the self-financing of some patients; for companies that do not choose drugs, not only are under pressure to cut and cut prices, but they are also at risk of lowering their health-care payment standards Whether it is the unselected products, or the original research drugs, can not escape the fate of price reduction Even if a large part of the market share is lost, there are still many pharmaceutical companies to take the initiative to reduce prices It is clear that many pharmaceutical companies are reducing prices due to the dual impact of the market and policy price reduction, may also retain the remaining market, if not cut prices, it is really eliminated by the market original title: These pharmaceutical companies, take the initiative to reduce prices! GSK, Howson, Hengrui, Xinlitai...